R&D Trends

Nordion enters into agreement to divest targeted therapies business to BTG

Wednesday, May 29, 2013 11:11 AM

Nordion, a provider of products and services for the prevention, diagnosis and treatment of disease, has entered into an agreement to divest its targeted therapies business to BTG, an international specialist healthcare company based in London, for a cash purchase price of $200 million. The transaction is anticipated to be completed by the end of June 2013.

More... »

Cenix BioScience, Debiopharm Group to identify predictive biomarkers

Wednesday, May 29, 2013 10:47 AM

Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a global Swiss biopharmaceutical group of companies focused on prescription drugs that target unmet medical needs, including oncology and companion diagnostics, have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

More... »

Elsevier launches new open access journal, Translational Proteomics

Wednesday, May 29, 2013 09:34 AM

Elsevier, a provider of scientific, technical and medical information products and services, launched Translational Proteomics, an online-only, open access journal devoted to transferring fundamental discoveries in the field of proteomics to clinical applications, accelerating understanding and treatment of human diseases.

More... »

J&J pharma segment poised with over 10 potential new product filings by 2017

Friday, May 24, 2013 01:28 PM

At a meeting with industry analysts, senior leaders from the Janssen Pharmaceutical companies of Johnson & Johnson announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.

More... »

Cardeas Pharma completes $34M in Series B financing

Friday, May 24, 2013 10:59 AM

Cardeas Pharma, a biopharmaceutical company focused on multi-drug resistant (MDR) bacterial infections, has completed a $34 million Series B round of financing.

More... »

Corgenix, Eli Lilly ink diagnostic development agreement

Friday, May 24, 2013 10:31 AM

Corgenix Medical, a worldwide developer and marketer of diagnostic test kits, has entered into a collaboration agreement with global pharmaceutical company Eli Lilly to develop diagnostic technology in support of a Lilly oncology pipeline program. The pair will collaborate to further advance this proprietary diagnostic technology originally developed by Lilly.

More... »

Grifols, Aradigm sign licensing agreement to develop, commercialize Pulmaquin

Wednesday, May 22, 2013 12:14 PM

Grifols, a global healthcare company, and Aradigm, an emerging specialty pharmaceutical company focused severe respiratory diseases, have signed an exclusive worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed phase IIb clinical trials in BE patients with Pulmaquin and Lipoquin.

More... »

VentureHealth launches new model for funding healthcare innovations

Wednesday, May 22, 2013 11:53 AM

VentureHealth, an online healthcare investment portal for accredited investors, has announced a new model for equity crowdfunding. Focused on innovations that dramatically improve clinical outcomes, VentureHealth is the first equity crowdfunding portal founded by professional investors. The investment platform offers qualified investors access to life sciences deals that traditionally were reserved for venture capitalists.

More... »

UCB, IBM collaborate to personalize care for epilepsy patients

Wednesday, May 22, 2013 11:05 AM

UCB, a Belgium-based global biopharmaceutical company focused on diseases of the immune system and central nervous system, and IBM have completed the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the transformative power of cognitive computing capabilities, such as IBM Watson, for epilepsy care.

More... »

Nordion, Navidea Biopharmaceuticals ink contract manufacturing agreement

Wednesday, May 22, 2013 10:12 AM

Nordion, a provider of products and services to the global health science market, has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. Nordion will manufacture [123I] NAV5001 a diagnostic imaging agent used to detect Parkinsonian syndromes and dementia with Lewy bodies.

More... »